A phase Ib clinical trial (NCT02179918) evaluated the anti-tumor activity of 4-1BB agonistic antibody in combination with PD-1-blocking mAb (Pembrolizumab) in patients with advanced solid tumors. The gene discussed is PDCD1; the disease is neoplasm.